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Two concepts of the value of a QALY (or the 
cost-effectiveness threshold)
Budget constrained systems
Freely funded systems
Opportunity cost value of a QALY (k)
What health is forgone as new (more 
costly) technologies displace existing 
services?
Consumption value of a QALY (v)
What value to individuals place on 
health in terms of their 
consumption of other good and 
services?
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Why does k matter?
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What it is and what its not
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How does it change?
• Need k what ever view of social value
• What it’s not
– Consumption value of health (v)
– Marginal productivity of ideal NHS
• No simple relationship to changes in budget and prices
– Discretionary expenditure
– Changes in productivity
• Stop doing things the NHS shouldn't do (increase k)
• Improve those things it should do (reduce k)
• Health production outside NHS
– Complement, e.g., longer life expectancy (reduce k)
– Substitute, e.g., reduced base line risk (increase k)
What NICE currently says (1)
Below a most plausible ICER of £20,000 per QALY gained, the 
decision to recommend the use of a technology is normally based on 
the cost-effectiveness estimate and the acceptability of a technology 
as an effective use of NHS resources.  
Above a most plausible ICER of £20,000 per QALY gained, 
judgements about the acceptability of the technology as an effective 
use of NHS resources will specifically take account of the following 
factors.
• The degree of certainty around the ICER...
• Whether there are strong reasons to indicate that the assessment of 
the change in HRQL has been inadequately captured...
• The innovative nature of the technology...
What NICE currently says (2)
Above a most plausible ICER of £30,000 per QALY gained, the 
Committee will need to identify an increasingly stronger case for 
supporting the technology as an effective use of NHS resources, with 
regard to the factors listed above.
Source:  National Institute for Health and Clinical Excellence (NICE). Guide to the 
Methods of Technology Appraisal. London: NICE; 2008.
Prioritising NICE’s methodological requirements 
Review recent key 
policy papers
Email survey
Focussed review 
of journal articles
Interviews
Workshop
Feedback via web
Report
Longworth et al. MRC-NICE scoping project: identifying the national institute for health and 
clinical excellence’s methodological research priorities and an initial set of priorities.  CHE 
Research Report 51, 2009. http://www.york.ac.uk/che/publications/in-house/ 
How can we estimate it?
• Informed judgement of the cost-effectiveness of things the 
NHS does and doesn’t do
• Infer a threshold from past decisions
• Find out what gets displaced and estimate its value
• Estimate the relationship between changes in expenditure 
and outcomes 
Informed judgement
Rawlins and Culyer, The National Institute for Clinical Excellence and its value judgments.  BMJ 2009; 
BMJ 2004;329:224-227 doi:10.1136/bmj.329.7459.224 (Published 22 July 2004)
Problems with informed judgement
• Lacks transparency
• May have no link with real opportunity costs
Inferring the threshold from past decisions
Source: Devlin N, Parkin D. Health Economics 2004;13:437-52.
Issues with inference from past decisions
• More recent results confirm general findings
• Important use of formal methods
• As other criteria are used in decisions, threshold is not 
revealed
– Decisions reflect (informal) weighting of QALYs gained
– NICE may consider technologies for ‘high priority’ patients
Studying local decisions
• Opportunity costs fall on local decision makers
• Can we estimate the threshold by measuring:
– What is displaced locally by new technologies?
– The value (cost per QALY gained) of what is displaced?
• Few data collected routinely on displaced services
• Major research activity needing frequent review
• Poor data on cost effectiveness of services
• How relevant to NICE’s decision?
A sample of 6 NHS commissioners and 16 providers
Source: Appleby J, et al. 
Searching for cost effectiveness 
thresholds in the NHS. Health 
Policy (2009),
doi:10.1016/j.healthpol.2008.12.0
10
Estimating relationship between expenditure 
and outcomes
• Variations in expenditure and outcomes within 
programmes
• Reflects what actually happens in the NHS
• Estimates the marginal productivity (on average) across 
the NHS 
• Earlier work has provided initial estimates
Relationship between expenditure and outcomes
• Earlier work has generated some initial estimates
– Martin et al. The link between health spending and health outcomes for the 
new English primary care trusts. London: The Health Foundation; 2009.
– Martin et al. The Link Between Health Care Spending and Health Outcomes 
for the New English Primary Care Trusts.  Centre for Health Economics (CHE) 
Research Paper No. 42. York: CHE, University of York; 2008.
– Martin et al. Does health care spending improve health outcomes?  Evidence 
from English programme budgeting data. Journal of Health Economics. 
2008;27:826–42.
Cancer Circulation Respiratory Gastro-int Diabetes
04/05   per LY
per QALY
£13,137
(£19,070)
£7,979
(£11,960)
05/06   per LY £13,931 £8,426 £7,397 £18,999 £26,453
Future work going forward
• More programmes
• How changes in overall expenditure gets allocated 
across all the programmes
• How changes in mortality might translate into QALYs 
gained
• How uncertain any overall estimate will be
• How it changes with scale of expenditure change
• How it changes over time (panel data)
• Workshop May 2011
• Completion June 2012
• http://www.york.ac.uk/che/research/teams/teehta/projec
ts/methodological-research/
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How can we estimate it?
ΔB, variation in overall expenditure
Expenditure equations,  elasticity of programme expenditure (%ΔE/%ΔB)
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Outcome equations,  elasticity of outcome (%ΔM/%ΔE)
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Illustrative results
Share of change 
in total
expenditure
Cost per life 
year gained
Cost per QALY 
gained (proportion 
of patients in ICD)
Cost per QALY gained 
(contribution to variance
in PBC expenditure
Big 4 PBCs 14.93% £12,824
11 PBCs 
(with mortality) 
29.12% £23,924
All 23 PBCs * 100% £27,039
2006 expenditure and mortality data for 2006-08 (2MFFs)
*Assumes same health effects per £ as the 11 PBCs with outcome data for the remaining 11 PBCs.  
‘Other’ (GMS) is assumed to have no health effects.   
Any health effects of GMS expenditure is through other PBCs
£8,773
£13,621
£15,395
£9,613
£14,904
£16,844
What we still need to do?
• How do changes in mortality translate into QALYs gained?
– DALY ratio overestimates QALYs gained
• What about PBCs with no mortality?
– Which PBCs and ICDs matter most (effect on overall threshold)
– Estimates of CE greater or less than overall estimate?
– How might we use future routine data
• How uncertain is any overall estimate?
– Estimated parameters, model identification and correlation
– Certainty equivalent for the threshold
• How it changes with scale of expenditure change?
• How it changes over time
– 7 years of expenditure and outcome data
– Panel  with more complex lag structure 
Representing uncertainty in the estimates?
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